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Background: External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen
deprivation therapy (ADT) is an established treatment option to prolong survival for
patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral
gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this
clinical setting in comparison with degarelix, an injectable GnRH antagonist.
Objective: To evaluate the safety and efficacy of relugolix to achieve and maintain
castration.
Design, setting, and participants: A phase 2 open-label study was conducted in 103 in-
termediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT
between June 2014 and December 2015.
Intervention: Patients randomly assigned (3:2) to 24-wk treatment with either daily
oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
Outcome measurements and statistical analysis: The primary endpoint was the rate of
effective castration (testosterone <1.73 nmol/l) in relugolix patients between 4 and 24 wk
of treatment. Secondary endpoints included rate of profound castration (testosterone <0.7
nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL)
assessed using the Aging Males’ Symptoms scale, and the European Organization for
Research and Treatment of Cancer (EORTC) Quality of Life (30-item EORTC core question-
naire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25])
questionnaires, and safety. No formal statistical comparisons with degarelix were planned.
Results and limitations: Castration rates during treatment were 95% and 82% withd 6
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tively. Median time to castration in the relugolix arm was 4 d. During treatment, PSA
levels and prostate volumes were reduced in both groups. Three months after disconti-
nuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone
recovery (statistical significance of differences not tested). Mean and median QoL scores
improved following treatment discontinuation. The most common adverse event was
hot flush (relugolix 57%; degarelix 61%). Lack of blinding was a potential limitation.
Conclusions: Relugolix achieved testosterone suppression to castrate levels within days
and maintained it over 24 wk with a safety profile consistent with its mechanism of
action.
Patient summary: Oral once-daily relugolix may be a novel oral alternative to injectable
androgen deprivation therapies.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Androgen deprivation therapy (ADT) with radiotherapy is an
appropriate treatment option for most men with newly
diagnosed intermediate- and high-risk prostate cancer (PCa)
[1]. While the timing and duration of neoadjuvant/adjuvant
ADT have not been defined fully, based on evidence from
several large studies [2–5], European and American clinical
practice guidelines suggest that 4–6 mo of ADT may be
sufficient for patients with intermediate-risk disease, where-
as patients with high-risk advanced localised disease are
more likely to benefit from prolonged neoadjuvant/adjuvant
treatment of 18–36 mo [6–10]. Meta-analyses have shown
benefit from both short and long courses of ADT [11,12].
Established ADT options are gonadotropin-releasing  hor-
mone (GnRH) analogues administered subcutaneously or
intramuscularly in a depot formulation. While effective in
achieving castration, GnRH agonists are associated with
potential worsening of genitourinary and other symptoms
due to a testosterone flare within 14 d of initial injection,
which may be symptomatic in advanced PCa, requiring
additional use of an antiandrogen [13,14]. Historically,
injectable GnRH agonists were developed because neither
oral small molecules nor peptide antagonists with the
requisite safety and efficacy to block the GnRH pathway
could be identified [15]. Degarelix, an approved once-monthly
injectable GnRH receptor antagonist, can rapidly reduce
testosterone levels without the initial testosterone surge, and
has been suggested to delay the time to the castration-
resistant disease state [16–19]. However, this GnRH antago-
nist requires monthly high-volume injections that are
commonly associated with injection-site reactions [20].
Relugolix (TAK-385) is an investigational, highly selec-
tive, orally active, nonpeptide GnRH receptor antagonist
[15,21]. As a potent oral agent, relugolix has the potential to
eliminate the need for injections while rapidly decreasing
testosterone and prostate-specific antigen (PSA) levels. In a
phase 1 study in healthy men, once-daily relugolix was
effective in lowering testosterone to below castration levels
(1.73 nmol/l or <50 ng/dl) [22]. Subsequent research
defined the efficacious dose range for further development
as 80–160 mg daily with a single loading dose of 320 mg to
achieve a rapid testosterone-lowering response [22]. Finally,
the half-life of 36–65 h [22] suggests that testosteronePlease cite this article in press as: Dearnaley DP, et al. The Oral Gona
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to Externarecovery after short-term or intermittent ADT should be
more rapid with relugolix than with depot formulations of
GnRH analogues. The safety of relugolix in these earlier
studies has been consistent with other ADT options [14,22].
The primary objective of this phase 2 study was to evaluate
whether relugolix results in rapid and sustained testosterone
suppression in men with intermediate-risk PCa who require
6 mo of neoadjuvant/adjuvant ADT in conjunction with
external beam radiotherapy (EBRT). Secondary objectives
included evaluation of the effects of relugolix on the kinetics
of testosterone suppression and recovery, PSA levels, prostate
volume, quality of life (QoL), and safety/tolerability. A
degarelix arm was included in the study to serve as a
contemporary ADT benchmark for qualitative comparisons.
A second phase 2 study evaluating relugolix in men with
advanced PCa and including a leuprolide arm for qualitative
comparison (ClinicalTrials.gov identifier NCT02083185) will
be reported in a subsequent publication.
2. Patients and methods
2.1. Patients
Eligible patients had histologically confirmed, localised,
intermediate-risk prostate adenocarcinoma with indication
for 24 wk of neoadjuvant/adjuvant ADT to EBRT. High-risk
patients were also considered for inclusion if, based on
physician judgement, they were deemed likely to benefit
from 6 mo of ADT. A complete list of eligibility criteria is
provided in the Supplementary material (Methods) and
Supplementary Table 1. A total of 103 patients were enrolled
in the USA (18 sites) and UK (five sites).
This study was approved by two central institutional
review boards and conducted in accordance with the
Declaration of Helsinki (2013 revision) and Good Clinical
Practice guidelines. All patients provided written informed
consent.
2.2. Study design and treatments
This was a phase 2 randomised, open-label, parallel-group
study conducted between June 2014 and December 2015
(ClinicalTrials.gov identifier NCT02135445). The trial was
not blinded. Patients were randomised in a 3:2 ratio todotropin-releasing Hormone Receptor Antagonist Relugolix as
l Beam Radiotherapy in Patients with Localised Intermediate-
Table 1 – Patient demographics and baseline characteristics.
Characteristic Relugolix 120 mg QD(N = 65) Degarelix 80 mg Q4W (N = 38)
Race, n (%)
White 58 (89) 31 (82)
Black or African American 7 (11) 7 (18)
Median (IQR) age (yr) 71.0 (67–73) 70.5 (67–75)
ECOG PS 0/1, a n (%) 60 (92)/4 (6) 33 (87)/4 (11)
Median (IQR) time since initial diagnosis (yr) 0.2 (0.1–0.3) 0.1 (0.1–0.2)
Gleason score, b n (%)
6 5 (8) 2 (5)
7 40 (62) 26 (68)
8 5 (8) 3 (8)
9 2 (3) 2 (5)
Primary tumour (T), n (%)
Not available 11 (17) 8 (21)
T1 21 (32) 12 (32)
T2 6 (9) 5 (13)
T2a 12 (18) 3 (8)
T2b 7 (11) 1 (3)
T2c 7 (11) 7 (18)
T3 1 (2) 1 (3)
TX 0 1 (3)
Regional lymph nodes (N), n (%)
N0 39 (60) 19 (50)
NX c 26 (40) 19 (50)
PSA (mg/l)
Mean (SD) 9.4 (6.0) 14.6 (21.0)
Median (IQR) 7.3 (4.8–12.9) 7.3 (5.5–11.2)
ECOG PS = Eastern Cooperative Oncology Group performance status; IQR = interquartile range; PSA = prostate-specific antigen; QD = once daily; Q4W = once
every 4 wk; SD = standard deviation.
a ECOG PS was missing for one patient in each group.
b Total Gleason score was missing for 13 and five patients in the relugolix and degarelix groups, respectively.
c NX includes unknown, not available, and missing regional lymph node data.
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mg on day 1 and 120 mg daily thereafter) or degarelix as a
subcutaneous depot injection (loading dose of 240 mg on
day 1, and then 80 mg every 4 wk). Patients were
randomised sequentially by study centre. No stratification
was implemented in the computer-generated randomisa-
tion schedule. Unique randomisation numbers were
assigned to patients using a centralised interactive voice/
web response system. The inclusion of degarelix provided a
contemporary GnRH antagonist benchmark for relugolix,
using the same assays and assessments. EBRT was initiatedTable 2 – Castration rates for patients who received at least one dose o
Relugolix 120 m
Castration rate a over 24 wk
n (%) 62 (95) 
90% CI b (one sided, lower bound) 90.0
95% CI b (two sided) 87.1–99.0 
Profound castration rate c over 24 wk
n (%) 53 (82) 
90% CI b (one sided, lower bound) 73.9 
95% CI b (two sided) 70.0–90.1 
CI = confidence interval; QD = once daily; Q4W = once every 4 wk.
a Castration rate was defined as the estimated proportion of patients with testos
4 through 24 wk.
b The 90% one-sided and the 95% two-sided CIs were calculated using exact met
c Rate of profound castration was defined as the estimated proportion of patients 
from week 13, day 1 through to week 25, day 1.
Please cite this article in press as: Dearnaley DP, et al. The Oral Gona
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to Externaafter 12–16 wk of ADT, as per each clinical site’s standard of
care.
The protocol did not specify the use of adjunctive
medications such as calcium and vitamin D, but these could
have been given at the clinician’s discretion.
Patients were evaluated on days 1, 2, and 4 during
week 1; once in each of weeks 2, 3, and 5; every 4 wk
thereafter during the 24-wk treatment period; and for
12 wk after treatment discontinuation. Serum testoster-
one concentrations were assayed using a conventional
immunoassay at screening, and subsequently using liquidf treatment.
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Fig. 1 – Mean testosterone levels through week 24 and after treatment discontinuation. Mean (+SD) testosterone levels are presented over time,
including during treatment (24 wk) and during 12 wk of follow-up after study drug discontinuation. Note the break in the y axis and different scaling
of values <100 versus >200 ng/dl. Data for the two treatment arms are staggered along the x axis for legibility. The dotted lines indicate a castration
threshold of 1.73 nmol/l (50 ng/dl) or 0.7 nmol/l (20 ng/dl). The week-2 assessment in one patient in the relugolix group is omitted from this figure as
the value was 10 times the upper limit of normal and is believed to be a technical error. All other data from this patient are included in the analysis.
QD = once daily; Q4W = once every 4 wk; SD = standard deviation.
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MS). Serum PSA assays were performed by a central
facility (LabCorp). Prostate volume was measured using
transrectal ultrasound or magnetic resonance imaging at
baseline and at the next imaging assessment 8–12 wk
after initiating ADT. QoL was assessed via the 30-item
European Organisation for Research and Treatment of
Cancer core questionnaire (EORTC QLQ-C30) [23], the 25-
item EORTC prostate cancer module (EORTC QLQ-PR25)
[24], and the Aging Males’ Symptoms (AMS) scale
[25]. QoL assessments were completed at screening; at
baseline; after 4, 12, and 24 wk of treatment; 4 wk after
treatment discontinuation; and at the end-of-study visit
(36 wk after starting the study; 12 wk off treatment).
Treatment compliance was measured by a patient-
reported daily diary using a handheld electronic device.
2.3. Outcomes
The primary endpoint was the rate of effective castration,
between 4 wk and 24 wk of treatment, defined as the
estimated proportion of patients with testosterone con-
centrations <1.73 nmol/l (<50 ng/dl) at all scheduled visits.
A lower (profound) castration threshold was defined as
testosterone levels <0.7 nmol/l (<20 ng/dl). Secondary
endpoints included PSA response at 12 wk and PSA nadir
during treatment and follow-up, prostate volume 8–12 wkPlease cite this article in press as: Dearnaley DP, et al. The Oral Gona
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to Externaafter treatment, and the time to achieve effective castration
and testosterone recovery (recovery was defined as the
return of testosterone values to baseline or to >9.8 nmol/l
[>280 ng/dl]), changes in QoL during and after treatment,
and safety measures. Such measures included the incidence
and severity of treatment-emergent adverse events (AEs),
and changes in vital signs, laboratory studies, and electro-
cardiograms (ECGs). Additional assessments included oph-
thalmology examinations, bone densitometry, and serum/
urinary biomarkers of bone turnover and phospholipidosis.
2.4. Statistical analysis
Assuming a 95% effective castration rate (<1.73 nmol/l or
50 ng/dl) with relugolix treatment, 60 evaluable patients
provided >91% as the lower bound of a one-sided 90%
confidence interval (CI). The sample size for the degarelix
arm was based on historical estimates of castration rate
using 80-mg 4-wk depot dosing of >95% [26], and no more
than two patients were expected to fail the defined
successful castration endpoint. A total of 100 patients were
planned to be enrolled into the study. In addition to the one-
sided 90% CI for the primary endpoint, two-sided 95% CIs
were calculated for the primary endpoint and the secondary
endpoint of profound castration. No formal statistical
differences were sought or hypothesised between relugolix
and degarelix.dotropin-releasing Hormone Receptor Antagonist Relugolix as
l Beam Radiotherapy in Patients with Localised Intermediate-
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were summarised over time. Changes in QoL values over time
were analysed using linear mixed models. Time to castration
and time to testosterone recovery were analysed using the
Kaplan–Meier method. The safety population, defined as all
patients who received one or more doses of either study drug,
was used for all safety and efficacy analyses.
3. Results
A total of 103 patients were enrolled in this study. Sixty-
three of the 65 patients (97%) randomised to relugolix and
all 38 patients randomised to degarelix completed the 24-
wk treatment period and the 12-wk follow-up period. Two
patients in the relugolix arm did not complete the study:
one due to patient withdrawal and the other due to loss to
follow-up. All patients were included in efficacy and safety
analyses (Supplementary Fig. 1).
Patient demographics and baseline characteristics
(Table 1) and EBRT treatment details (Supplementary Table 2)
were similar between treatment groups. Most patients had40 Mean PSA change: –88.1%
≥50% PSA reduction, n (%): 64 (98)
≥90% PSA reduction, n (%): 36 (55)
Mean PSA change: –97.4%
≥50% PSA reduction, n (%): 64 (98)






























































Fig. 2 – Individual PSA responses of patients in the relugolix and degarelix gro
patients at week 12 (neoadjuvant) and week 24 (neoadjuvant/adjuvant/EBRT) f
responses. Dotted lines indicate the PSA50 and PSA90 thresholds, respectively. 
PSA50 = reduction in PSA by 50%; PSA90 = reduction in PSA by 90%. a Last o
Please cite this article in press as: Dearnaley DP, et al. The Oral Gona
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to Externaintermediate-risk disease; however, two patients in each
group with Gleason 9 PCa and one patient in each group with
T3 disease were allowed per protocol based on investigator
discretion despite higher-risk disease. Overall, 18 patients had
missing Gleason scores that the contract research monitoring
team was unable to document at the enrolling sites. Median
compliance with study drug, as measured with the electronic
patient diary, was >98% in both arms.
As shown in Table 2, both relugolix and degarelix were
associated with high rates of effective castration, with
conventional castration rates of 95% and 89%, respectively. A
sensitivity analysis including only patients with intermedi-
ate-risk disease yielded similar results (Supplementary
Table 3). The profound castration rates for the lower
threshold of 0.7 nmol/l (20 ng/dl) were 82% in the relugolix
group and 68% in the degarelix group. Mean testosterone
levels across 24 wk of treatment and 12 wk of follow-up
after discontinuation of treatment are reported in Fig. 1 and
Supplementary Table 4. The time to castration was rapid in
both groups, at a median of 4 d in the relugolix group and 3 d
in the degarelix group.Patients
Mean PSA change: –85.7%
≥50% PSA reduction, n (%): 37 (97)
≥90% PSA reduction, n (%): 18 (47)
Mean PSA change: –96.3%
≥50% PSA reduction, n (%): 38 (100)



















ups. Waterfall plots of reduction in PSA percentage for individual
or relugolix and degarelix, as well as associated PSA50 and PSA90
EBRT = external beam radiotherapy; PSA = prostate-specific antigen;
bservation carried forward.
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24 wk, testosterone levels recovered rapidly within
12 wk; recovery to baseline or >9.8 nmol/l (280 ng/dl)
occurred in 52% of patients. In the degarelix group, median
testosterone remained well below 1.73 nmol/l (<50 ng/dl)
following discontinuation, with only 16% of patients
meeting the protocol-specified definition of testosterone
recovery to baseline or >9.8 nmol/l. The time to testoster-
one recovery is depicted in Supplementary Fig. 2.
In both groups, the median prostate volume decreased
from baseline to 8–12 wk of treatment (relugolix 26% and
degarelix 29%; Supplementary Table 5). Similarly, median PSA
levels declined steadily through week 24 (Supplementary
Table 6). Waterfall plots of individual PSA percentage
reductions at weeks 12 and 24 are shown in Fig. 2. By
12 wk, the reduction in PSA by 50% in both groups was
97%, and the reduction in PSA by 90% was 55% and 47% in
the relugolix and degarelix groups, respectively. Median PSA
levels remained low after treatment discontinuation in both
arms (Supplementary Table 4). Both luteinising hormone (LH)
and follicle-stimulating hormone (FSH) levels were sup-
pressed on treatment with both relugolix and degarelix
(Supplementary Table 4).
Global health status, as assessed by EORTC-QLQ-C30, and
sexual activity and hormonal treatment-related symptoms, as
assessed by the EORTC-QLQ-PR25, were negatively affected
during treatment in both groups (Table 3). Within 12 wk after
treatment discontinuation, sexual activity scores improved by
a mean of 12.1 for relugolix and 6.6 for degarelix (median
8.3 and 0.0, respectively) and hormonal treatment-related
symptoms changed by a mean of –5.0 and –1.2 (median 5.6
and 0.0), respectively.
Similarly, AMS total and subscale scores (sexual, psycho-
logical, and somatic) worsened during treatment in both
groups (Table 3 and Supplementary Table 7). After treatment
discontinuation, the mean percentage change in AMS total
scores was –15% in the relugolix group and –2.9% in the
degarelix group. Median percentage changes were consistent
(–16% and –3.9%, respectively). Similar patterns were
observed in the subscale scores (Supplementary Table 7).
At least one AE was reported by most patients in both
groups (relugolix 86%; degarelix 97%), although severe (grade
3 or higher) AEs were infrequent (relugolix 2%; degarelix 11%).
The most common AE in both groups was hot flush (relugolix
57%; degarelix 61%). Except for findings of increased alanine
aminotransferase (13%) and injection-site erythema (11%) in
the degarelix group, the overall AE profile was similar
between relugolix and degarelix (Table 4). There were no
differences between groups in ophthalmology findings,
laboratory findings, ECGs, or biomarkers of bone turnover,
bone density, or phospholipidosis. No patients in either group
discontinued treatment due to AEs.
4. Discussion
In this phase 2 study of intermediate-risk PCa patients, adding
neoadjuvant/adjuvant relugolix to EBRT resulted in a 95% rate
of sustained castration. While the study was not designed or
powered to make formal statistical comparisons betweenPlease cite this article in press as: Dearnaley DP, et al. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-
Table 4 – Most common (10%) all-cause and grade 3 treatment-emergent adverse events (safety population).
n (%) Relugolix 120 mg QD (N = 65) Degarelix 80 mg Q4W (N = 38)
Grade 1–2 Grade 3 Grade 1–2 Grade 3
Any AE a 56 (86) 1 (2) 37 (97) 4 (11)
Hot flush b 37 (57) 0 23 (61) 0
Fatigue 17 (26) 0 6 (16) 0
Diarrhoea 12 (18) 0 5 (13) 0
Cataract 10 (15) 0 7 (18) 0
Nocturia 9 (14) 0 5 (13) 0
Pollakiuria 8 (12) 0 6 (16) 0
Dysuria 5 (8) 0 6 (16) 0
Increased blood testosterone 2 (3) 0 4 (11) 0
Decreased urine flow 1 (2) 0 4 (11) 0
Increased ALT 0 0 5 (13) 0
Injection-site erythema 0 0 4 (11) 0
Bone fracture c 0 0 0 1 (3)
Paranasal sinus haematoma 0 0 0 1 (3)
Pleural effusion 0 0 0 1 (3)
Ulcerative oesophagitis 0 0 0 1 (3)
Pulmonary contusion 0 0 0 1 (3)
Road traffic accident 0 0 0 1 (3)
Diabetes mellitus 0 0 0 1 (3)
Malignant mesothelioma 0 0 0 1 (3)
Cold sweat 0 0 0 1 (3)
Headache 0 1 (2) d 0 0
Hypertension 0 1 (2) d 0 0
AE = adverse event; ALT = alanine aminotransferase; QD = once daily; Q4W = once every 4 wk.
a Concomitant medications to manage any AE were taken by 52% (34/65) of patients in the relugolix arm and 71% (27/38) in the degarelix arm. Calcium and/or
vitamin D was taken by 32% (21/65) and 37% (14/38), respectively.
b Drugs to treat hot flushes were taken by 6% (4/65) of patients in the relugolix arm and 11% (4/38) in the degarelix arm.
c Bone fracture includes ankle, fibula, radius, ulna, jaw, rib, and facial bone fractures that occurred in a road traffic accident in a single patient.
d These events occurred in a single patient.
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maintained castration during the treatment period. Accord-
ingly, effects on PSA response and prostate volume were
consistent between relugolix and degarelix groups, as well as
consistent with data previously reported with other GnRH
analogues [26–28]. Both relugolix and degarelix yielded rapid
reductions in testosterone not seen with GnRH receptor
agonists, which are associated with an early testosterone
flare. Furthermore, both LH and FSH are fully suppressed
while on treatment with both relugolix and degarelix,
whereas GnRH agonists do not fully suppress FSH [19].
The rate of gonadotropin and testosterone recovery after
treatment discontinuation was rapid with relugolix. These
findings are consistent with its pharmacokinetic profile as a
daily oral therapy. Fast testosterone recovery with relugolix
was associated with a rapid improvement in a range of
castration-related symptoms on QoL measures.
Previous data suggest that recovery from degarelix
monthly depot injections can take >100 d; in this study,
only 16% of degarelix patients had testosterone recovery 84 d
after treatment discontinuation. Similar delayed recovery of
testosterone has been reported using GnRH agonists,
particularly with the 3-mo depot preparations [29,30].
The ability to personalise dosing strategies with a once-
daily oral medication with reliable rapid return of
testosterone and fast relief from symptoms related to
ADT may be advantageous for patients who do not want
injections, those receiving a specific duration of therapy,
those with disease eligible for intermittent therapy, andPlease cite this article in press as: Dearnaley DP, et al. The Oral Gona
Neoadjuvant/Adjuvant Androgen Deprivation Therapy to Externaelderly patients with comorbidities or acute intercurrent
illnesses where fatigue and muscle wasting are problematic.
Both relugolix and degarelix were well tolerated in this
study. Although the frequency and type of AEs were not
compared between the treatment arms with formal
statistical analyses, similar patterns of AEs were reported
by patients in both groups, with hot flush and fatigue being
the most common. No hepatic-related AEs occurred in
either group that resulted in dose modification or treatment
discontinuation. Several patients receiving degarelix had
injection-site reactions, consistent with past observations
with injectable GnRH analogues. With the exception of
those local reactions, the incidence and pattern of AEs with
relugolix were as expected for a GnRH receptor antagonist
[31]. Overall, there were no unexpected safety findings, no
evidence of any bone safety or ophthalmological findings,
no evidence of drug-induced phospholipidosis, and no
safety concerns identified that would limit treatment in
most patients.
The lack of blinding in this study is a potential limitation.
Although knowledge of treatment assignments is unlikely to
have had a meaningful impact on testosterone levels or other
pharmacodynamic endpoints, it could have influenced
investigators’ assessments of safety and patients’ responses
on QoL questionnaires.
Despite the high compliance reported for relugolix
administration in this study (>98%), another potential
limitation of the trial is that it may not reflect compliance
and adherence in a real-world setting. Inconsistent dosingdotropin-releasing Hormone Receptor Antagonist Relugolix as
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suboptimal treatment outcomes. Although compliance is
more difficult to monitor with self-administered oral
medications compared with injections administered by
healthcare professionals, compliance can be monitored
indirectly with testosterone or PSA levels. Novel strategies
are being developed to improve adherence to oral oncology
drugs [32]. Studies with longer-term follow-up are needed to
further evaluate the clinical impact of more rapid testosterone
recovery with relugolix, as well as long-term suppression of
both FSH and LH. The phase 3 HERO trial investigating
relugolix versus leuprolide over 48 wk is on-going in patients
with advanced PCa (NCT03085095) and will evaluate
whether relugolix can suppress testosterone through
48 wk in men with advanced PCa. This study will also
evaluate whether relugolix can prolong the time to the
castration-resistant PCa as compared with leuprolide acetate.
Recently released guidelines on the management of
patients with localised intermediate-risk PCa recommend
ADT with radiotherapy as a standard treatment option
[33]. Considering the limitations of injectable GnRH agonists
and GnRH receptor antagonists, there is an unmet need for a
novel ADT in this treatment landscape. While other oral GnRH
receptor antagonists are currently in development for
women’s health indications [34], to our knowledge, relugolix
is the only such antagonist in clinical development for PCa.
5. Conclusions
In summary, 24-wk treatment with the oral GnRH receptor
antagonist relugolix rapidly and effectively reduced and
sustained testosterone to castration levels, while exhibiting
a well-tolerated safety profile. A global phase 3 trial is on-
going to further evaluate the efficacy and safety of relugolix
in men with PCa.
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